Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.
The interventions involved in this study are:
A randomized phase II trial of carboplatin with or without nivolumab in first-line metastatic triple-negative breast cancer
- ClinicalTrials.gov Identifier: NCT03414684
- Protocol Number: 17-512
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required